Brawn Biotech Ltd (BRAWN) — shareholding pattern, promoter holding, financials and share price
About Brawn Biotech Ltd (BRAWN)
Brawn Biotech Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as BRAWN and on the BSE under scrip code 530207. Its ISIN is INE899B01015.
Incorporated in 1985, Brawn Biotech Ltd is in the business of trading pharmaceutical products [1]
Brawn Biotech Ltd is a wholesale distributor of pharmaceutical and medical goods, offering a wide range of products including herbals, Ayurvedic, and critical care items.
The company has international presence, marked by substantial growth in sales and profits due to its robust distribution network across global markets.
Listed peers in Pharmaceuticals: Colinz Laboratories Ltd, Vivanza Biosciences Ltd, Ganga Pharmaceuticals Ltd, Decipher Labs Ltd, Fabino Enterprises Ltd, Shyama Computronics and Services Ltd.
Valuation & Returns
10 Jul 2026At ₹21.03 a share on 10 Jul 2026, Brawn Biotech Ltd (BRAWN) was valued at a price-to-earnings ratio of 6.71x against an industry P/E of 36.41x and a price-to-book of 1.88x on a book value of ₹11.21 per share as of Mar 2025. Solomo computes return on equity of 27.96% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 6.71x
- Industry P/E
- 36.41x
- P/B
- 1.88x
- EPS (TTM)
- ₹3.13
- Book value / share
- ₹11.21
- ROE
- 27.96%
- ROA
- 4.59%
- Debt / equity
- 0x
- Dividend yield
- 0%
- 52-week range
- ₹16.66 – ₹24.37
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2023In the year ended Mar 2023, Brawn Biotech Ltd (BRAWN) reported revenue of ₹0.48 crore, net profit of ₹0.19 crore and earnings per share of ₹0.63. Figures are consolidated, as filed with the exchanges.
In the quarter ended Jun 2023, revenue was ₹0.12 crore and net profit ₹-0.04 crore (consolidated).
| Metric | Mar 2023 |
|---|---|
| Revenue (₹ cr) | 0.48 |
| Net profit (₹ cr) | 0.19 |
| EPS (₹) | 0.63 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -12.94% | -22.96% | 16.03% | -18.37% |
| Profit growth | - | - | - | -39.20% |
| Stock price CAGR | -6% | -4% | 7% | 5% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 52.94% of Brawn Biotech Ltd (BRAWN) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0% and domestic institutional investors (DII) hold 0.35%. Market capitalisation was ₹6 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY 14.42%, DAKSHA KOTAK 1.24%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 52.94% | - | 0% | 0.35% | 47.06% |
| Mar 2026 | 52.94% | - | 0% | 0.35% | 47.06% |
| Dec 2025 | 53.39% | - | 0% | 0.35% | 46.61% |
| Sep 2025 | 53.66% | - | - | 0.35% | 46.34% |
| Jun 2025 | 53.66% | - | - | 0.35% | 46.34% |
| Mar 2025 | 53.66% | - | - | 0.35% | 46.34% |
| Dec 2024 | 53.64% | - | - | 0.35% | 46.36% |
| Sep 2024 | 53.64% | - | - | 0.35% | 46.36% |